Biotechnology

https://techpapersworld.com/wp-content/uploads/2024/11/CABIO-Deepens-Commitment-to-Global-1280x720.jpg

BiotechnologyCABIO Deepens Commitment to Global Markets, Aiming to Serve International Clients and Pursue Long-Term International Partnerships

CABIO, a high-tech enterprise underpinned by biotechnology and listed on the Science and Technology Innovation Board (stock code: 688089), unveiled its innovative product, NeoHMOs®, at the Food Ingredients Europe event held in Frankfurt, Germany. Recently, CABIO’s Human Nutrition Business Unit has made frequent appearances in international exhibitions, participating in events such as SupplySide West in Las Vegas, USA, and Food Ingredients Europe. These participations have facilitated discussions on future industry trends and cooperation with global partners. CABIO at...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/Pharmanovia-Signs-Novel-Biologic-In-Licensing-Agreement-1280x720.jpg

BiotechnologyPharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites

Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its oncology portfolio with a new licensing agreement for catumaxomab, for the treatment of malignant ascites. “Pharmanovia’s supportive care focus, broad European platform and strong expertise in the oncology space make them the ideal partner for us. We look forward to working together while continuing to further expand our pipeline...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Neurizons-NUZ-001-Reduces-1280x720.jpg

BiotechnologyNeurizon’s NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead candidate, NUZ-001. These innovative studies reveal NUZ-001’s unique mechanism of action in preventing the aggregation of TAR DNA-binding protein 43 (TDP-43), a key pathological feature of ALS, and the ability of NUZ-001 to significantly improve the electrophysiological dysfunction of TDP-43 M337V mutated motor...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/AbbVie-Receives-European-Commission--1280x720.jpg

BiotechnologyAbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. ELAHERE is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine approved in the European Union (EU), as well as Iceland, Liechtenstein, Norway, and Northern Ireland. “It’s been...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/Cancer-Targeted-Technology-Receives-Fast-1280x720.jpg

BiotechnologyCancer Targeted Technology Receives Fast Track $2.4M Grant to Develop an Innovative PSMA-Targeted Small Molecule Drug Conjugate for Prostate Cancer

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute awarded the Phase I portion ($400K) of the fast track Phase I/II ($2.4M) Small Business Innovation Research (SBIR) grant to develop a new drug to treat metastatic prostate cancer. The grant focuses on a promising new prodrug, CTT2274, that targets Prostate-Specific Membrane Antigen (PSMA) on prostate cancer and is designed to release a toxic...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/Anaergia-Awarded-Contract-to-Operate-and-Maintain-1280x720.jpg

BiotechnologyAnaergia Awarded Contract to Operate and Maintain Rialto Bioenergy Solutions Facility in California

Anaergia Inc. (“Anaergia”, the “Company”, “we”, “us”, or “our”) (TSX: ANRG) announced today that its subsidiary, Anaergia Services LLC (“Anaergia Services”), has entered into a long-term Operations and Maintenance (“O&M”) contract with Rialto Bioenergy Solutions LLC (“RBS”), an affiliate of Sevana Bioenergy LLC. The RBS facility (“Facility”) is the largest landfill diverted organic waste-to-renewable natural gas facility in North America. “We are pleased and proud to be entrusted in operating the RBS facility, that is...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/Immunovia-presents-model-development-study-1280x720.jpg

BiotechnologyImmunovia presents model-development study results at meeting of the Collaborative Group of the Americas–Inherited Gastrointestinal Cancers

Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company’s next-generation test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC). The Scientific Committee of the CGA-IGC evaluated and accepted Immunovia’s abstract, which reports outcomes from the company’s model-development study, for presentation at the meeting. Immunovia’s submission was also recognized for inclusion in the Henry Lynch Lecture during the...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/11/GenSight-Biologics-Announces-Submission--1280x720.jpg

BiotechnologyGenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the submission of the updated regulatory file for LUMEVOQ® gene therapy to the French medicines safety agency Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) to prepare for the restart of the early access (AAC) program in France. The submission documents the successful manufacture...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/VIVOLTA-Partners-with-Neurochase-to-Manufacture-1280x720.jpg

BiotechnologyVIVOLTA Partners with Neurochase to Manufacture Electrospun Micro-Catheters Delivering Advanced CNS Therapies to the Brain

VIVOLTA, the medical electrospinning solutions provider, has signed a long-term partnership with Neurochase, the CNS (central nervous system) delivery platform specialist, to manufacture electrospun micro-catheters to deliver advanced therapies to the brain. “The VIVOLTA relationship has been hugely important in finding a solution to one of the most technically challenging components of the Neurochase delivery system. We are excited to be taking our transformative product forward together into large scale manufacture with such a knowledgeable,...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/11/CARMATs-Aeson®-Artificial-Heart-Is-Gradually--1280x720.jpg

BiotechnologyCARMAT’s Aeson® Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), provides an update on Aeson® artificial heart’s uptake as a bridge to transplant in Europe. Growing adoption of Aeson® as a bridge-to-transplant solution in Europe By the end of October 2024, 30 patients had successfully undergone heart transplant after being supported by the...

Older Posts